US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% WDC $415.29 ▲+0.00% TSLA $370.59 ▲+0.00%
FinancialContent

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

27.00 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about KalVista Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
Halper Sadeh LLC is Investigating Whether RLYB, KALV, INM, TMHC are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Taylor Morrison Home Corporation (NYSE - TMHC), Rallybio Corporation (Nasdaq – RLYB), InMed Pharmaceuticals, Inc. (Nasdaq – INM), KalVista Pharmaceuticals, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000 ↗
This clinical-stage biotech focused on rare diseases reported a notable insider sale amid a year of strong stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq –
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether KALV, THR, CECO are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Unusual volume stocks in Wednesday's session ↗
Via Chartmill
News headline image
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
From Kahn Swick & Foti, LLC
Via Business Wire
Unusual volume stocks are being observed in Thursday's session. ↗
Via Chartmill
News headline image
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement ↗
On April 29, 2026, a rare-disease deal reshapes biotech M&A expectations as investors weigh tender terms. 
Via The Motley Fool
Topics Stocks
Wednesday's session: top gainers and losers ↗
Via Chartmill
Which stocks are moving on Wednesday? ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
KALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
Via Chartmill
News headline image
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health. 
Via The Motley Fool
News headline image
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
VR Adviser Adds Over 1 Million Savara Shares ↗
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
From KalVista Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >